Active Asset: AMC-882
AAV8 Vector for Hemophilia B
Current Valuation Est.
$45M - $60M
Novel adeno-associated virus (AAV) capsid variant demonstrating 4x enhanced liver tropism and reduced immunogenicity in non-human primates compared to benchmark AAV5 vectors.
Live Market Telemetry Live Sync
2 Days Ago • ClinicalTrials.gov
Competitor 'PharmaCorp X' initiated Phase 1/2 trial for AAV-mediated Hemophilia B therapy.
5 Days Ago • BioCentury
M&A Spike: Rare disease gene therapy acquisitions up 14% QOQ.
Active Pitch Framing
Baseline Value Proposition (Static)
"AMC-882 offers a highly efficient AAV vector for Hemophilia B with strong preclinical data indicating superior liver targeting."
Market-Adjusted Pitch (Dynamic)
"With rising M&A interest in rare disease vectors, AMC-882 provides a strategic derisking opportunity. Unlike standard vectors entering Phase 1/2, our 4x liver tropism specifically mitigates the immunogenicity hurdles currently plaguing the standard-of-care pipeline."